Primary Results on Safety and Efficacy From the LEADLESS II–Phase 2 Worldwide Clinical Trial

TY - JOUR

T1 - Primary Results on Safety and Efficacy From the LEADLESS II–Phase 2 Worldwide Clinical Trial

AU - LEADLESS II Investigators

AU - Reddy, Vivek Y.

AU - Exner, Derek V.

AU - Doshi, Rahul

AU - Tomassoni, Gery

AU - Bunch, T. Jared

AU - Estes, N. A.Mark

AU - Neužil, Petr

AU - Paulin, Frédéric L.

AU - Garcia Guerrero, Juan Jose

AU - Cantillon, Daniel J.

N1 - Funding Information: Dr Reddy has served as an unpaid consultant for Abbott; unrelated to this paper, has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera, Apama Medical, Aquaheart, Atacor, Autonomix, Backbeat, BioSig, Circa Scientific, Coria Medical, Dinova-Hangzhou Nuomao Medtech Co, East End Medical, EPD, Epix Therapeutics, EpiEP, Eximo, Fire1, Javelin, Kardium, Keystone Heart, LuxCath, Medlumics, Middlepeak, Nuvera, Sirona Medical, and Valcare; unrelated to this work, has served as a consultant for Axon, Biotronik, Cardiofocus, Cardionomic, CardioNXT/AFTx, EBR, Impulse Dynamics, Medtronic, Philips, Pulse Biosciences, Stimda, and Thermedical; and has equity in Manual Surgical Sciences, Newpace, Surecor, and Vizaramed. Dr Exner has served as a consultant for and receiving research support from Abbott. Dr Doshi has served as a steering committee member and as a consultant for Abbott. Dr Tomassoni has served as a consultant and a speaker for Abbott and Boston Scientific. Dr Bunch has served as a consultant for Abbott; and has received research grants from Altathera and Boston Scientific. Dr Estes has served as a consultant for Abbott, Medtronic, and Boston Scientific. Dr Paulin has received research support from Abbott; and has received honoraria and proctorship funding from Medtronic. Dr Garcia Guerrero has served as a consultant for and receiving research support from Abbott. Dr Cantillon has served as a consultant for Abbott and Boston Scientific. Dr Neužil has reported that he has no relationships relevant to the contents of this paper to disclose. Funding Information: Dr Reddy has served as an unpaid consultant for Abbott; unrelated to this paper, has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera, Apama Medical, Aquaheart, Atacor, Autonomix, Backbeat, BioSig, Circa Scientific, Coria Medical, Dinova-Hangzhou Nuomao Medtech Co, East End Medical, EPD, Epix Therapeutics, EpiEP, Eximo, Fire1, Javelin, Kardium, Keystone Heart, LuxCath, Medlumics, Middlepeak, Nuvera, Sirona Medical, and Valcare; unrelated to this work, has served as a consultant for Axon, Biotronik, Cardiofocus, Cardionomic, CardioNXT/AFTx, EBR, Impulse Dynamics, Medtronic, Philips, Pulse Biosciences, Stimda, and Thermedical; and has equity in Manual Surgical Sciences, Newpace, Surecor, and Vizaramed. Dr Exner has served as a consultant for and receiving research support from Abbott. Dr Doshi has served as a steering committee member and as a consultant for Abbott. Dr Tomassoni has served as a consultant and a speaker for Abbott and Boston Scientific. Dr Bunch has served as a consultant for Abbott; and has received research grants from Altathera and Boston Scientific. Dr Estes has served as a consultant for Abbott, Medtronic, and Boston Scientific. Dr Paulin has received research support from Abbott; and has received honoraria and proctorship funding from Medtronic. Dr Garcia Guerrero has served as a consultant for and receiving research support from Abbott. Dr Cantillon has served as a consultant for Abbott and Boston Scientific. Dr Neužil has reported that he has no relationships relevant to the contents of this paper to disclose.

PY - 2022/1

Y1 - 2022/1

UR - https://www.scopus.com/pages/publications/85122523856

U2 - 10.1016/j.jacep.2021.11.002

DO - 10.1016/j.jacep.2021.11.002

M3 - Letter

C2 - 34863657

AN - SCOPUS:85122523856

SN - 2405-500X

VL - 8

SP - 115

EP - 117

JO - JACC: Clinical Electrophysiology

JF - JACC: Clinical Electrophysiology

IS - 1

ER -